These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16759087)

  • 1. Dependence of molecular properties on proteomic family for marketed oral drugs.
    Vieth M; Sutherland JJ
    J Med Chem; 2006 Jun; 49(12):3451-3. PubMed ID: 16759087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral delivery of G protein-coupled receptor modulators: an explanation for the observed class difference.
    Beaumont K; Schmid E; Smith DA
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3658-64. PubMed ID: 15982884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution of synthetic oral drug properties.
    Proudfoot JR
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1087-90. PubMed ID: 15686918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug discovery beyond the 'rule-of-five'.
    Zhang MQ; Wilkinson B
    Curr Opin Biotechnol; 2007 Dec; 18(6):478-88. PubMed ID: 18035532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs in other drugs: a new look at drugs as fragments.
    Siegel MG; Vieth M
    Drug Discov Today; 2007 Jan; 12(1-2):71-9. PubMed ID: 17198975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of physiochemical property profiles of development and marketed oral drugs.
    Wenlock MC; Austin RP; Barton P; Davis AM; Leeson PD
    J Med Chem; 2003 Mar; 46(7):1250-6. PubMed ID: 12646035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Strategy of molecular design of drugs: the unification of macro-properties and micro-structures of a molecule].
    Guo ZR
    Yao Xue Xue Bao; 2008 Mar; 43(3):227-33. PubMed ID: 18630256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing active template molecules by combining computational de novo design and human chemist's expertise.
    Lameijer EW; Tromp RA; Spanjersberg RF; Brussee J; Ijzerman AP
    J Med Chem; 2007 Apr; 50(8):1925-32. PubMed ID: 17367122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure.
    Leach AG; Jones HD; Cosgrove DA; Kenny PW; Ruston L; MacFaul P; Wood JM; Colclough N; Law B
    J Med Chem; 2006 Nov; 49(23):6672-82. PubMed ID: 17154498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.
    Doak BC; Over B; Giordanetto F; Kihlberg J
    Chem Biol; 2014 Sep; 21(9):1115-42. PubMed ID: 25237858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escape from flatland: increasing saturation as an approach to improving clinical success.
    Lovering F; Bikker J; Humblet C
    J Med Chem; 2009 Nov; 52(21):6752-6. PubMed ID: 19827778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds.
    Morphy R
    J Med Chem; 2006 May; 49(10):2969-78. PubMed ID: 16686538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-based assays in GPCR drug discovery.
    Siehler S
    Biotechnol J; 2008 Apr; 3(4):471-83. PubMed ID: 18383022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries.
    Dobson PD; Patel Y; Kell DB
    Drug Discov Today; 2009 Jan; 14(1-2):31-40. PubMed ID: 19049901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the chemical properties of drugs and FEMA/FDA notified GRAS chemical compounds used in the food industry.
    Sprous DG; Salemme FR
    Food Chem Toxicol; 2007 Aug; 45(8):1419-27. PubMed ID: 17368904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative drug discovery approaches for orphan GPCRs.
    Levoye A; Jockers R
    Drug Discov Today; 2008 Jan; 13(1-2):52-8. PubMed ID: 18190864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of ligand efficiency metrics in drug discovery.
    Hopkins AL; Keserü GM; Leeson PD; Rees DC; Reynolds CH
    Nat Rev Drug Discov; 2014 Feb; 13(2):105-21. PubMed ID: 24481311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global mapping of pharmacological space.
    Paolini GV; Shapland RH; van Hoorn WP; Mason JS; Hopkins AL
    Nat Biotechnol; 2006 Jul; 24(7):805-15. PubMed ID: 16841068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules?
    Hou T; Wang J; Zhang W; Xu X
    J Chem Inf Model; 2007; 47(2):460-3. PubMed ID: 17381169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing better drugs: predicting cytochrome P450 metabolism.
    de Groot MJ
    Drug Discov Today; 2006 Jul; 11(13-14):601-6. PubMed ID: 16793528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.